Medivir
Medivir: Positive Safety Confirmed for MIV-818 (Redeye)
2021-04-19 15:40
Redeye views the safety update from the Phase Ib trial with MIV-818 as encouraging, albeit expected. The last patient in the Phase Ib monotherapy trial has been evaluated for safety with positive results. Medivir has consequently determined a recommended dose for the next phase.
info@redeye.se (Redeye.se)
Redeye AB - Redeye.se